Opinion|Videos|November 20, 2026

The One Bronchiectasis Model: Treating Beyond the Underlying Cause

Different causes of bronchiectasis may start differently, but Dr. Patrick Flume argues their downstream disease looks similar enough that therapies developed for one etiology can benefit many others.

Welcome back to another AJMC Insights series. In "The One Bronchiectasis Model: Treating Beyond the Underlying Cause," Patrick Flume, MD opens this second installment by introducing the one bronchiectasis model and explaining why a shared downstream disease process can unite so many different underlying causes.

Dr. Flume introduces the "1-BE," or one bronchiectasis, model as a framework for understanding how different underlying causes of bronchiectasis converge on a shared downstream pathology. He explains that etiologies like cystic fibrosis typically begin with impaired mucociliary clearance, which then triggers obstruction, inflammation, and infection. Immune deficiency, by contrast, often starts with infection, which then drives inflammation, airway injury, and impaired clearance. Regardless of the starting point, Dr. Flume says, these three processes, inflammation, obstruction, and infection, continuously feed one another and drive further structural airway damage, ultimately producing bronchiectasis.

Because the 1-BE model focuses on these downstream consequences rather than the original cause, Dr. Flume argues that a therapy targeting obstruction, infection, or inflammation does not need to address the underlying etiology to be effective. A treatment developed and validated in one condition, such as cystic fibrosis, can therefore reasonably be expected to help many patients whose bronchiectasis stems from an entirely different cause. Dr. Flume presents this as the clinical rationale behind the 1BE framing: since the structural disease process looks so similar across etiologies, researchers and clinicians can pursue shared therapeutic strategies instead of developing a separate treatment pathway for every possible cause. That shift in thinking, he suggests, has meaningfully broadened the pool of patients who stand to benefit from newer bronchiectasis therapies, even those originally studied in a narrower population like cystic fibrosis. It reframes bronchiectasis less as a collection of separate diseases and more as one shared structural and inflammatory process with many possible entry points.

The next episode in this series, "Bronchiectasis Standard of Care: Airway Clearance and Beyond," turns to what standard bronchiectasis management looked like before these newer targeted therapies arrived.


Related to this article